JP4708034B2 - 急性および慢性炎症、虚血およびリモデリング過程に対する治療剤としてのピリミジノン誘導体 - Google Patents
急性および慢性炎症、虚血およびリモデリング過程に対する治療剤としてのピリミジノン誘導体 Download PDFInfo
- Publication number
- JP4708034B2 JP4708034B2 JP2004571738A JP2004571738A JP4708034B2 JP 4708034 B2 JP4708034 B2 JP 4708034B2 JP 2004571738 A JP2004571738 A JP 2004571738A JP 2004571738 A JP2004571738 A JP 2004571738A JP 4708034 B2 JP4708034 B2 JP 4708034B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mono
- alkoxycarbonyl
- alkoxy
- alkylaminocarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *CC(*1CC*CC1)=O Chemical compound *CC(*1CC*CC1)=O 0.000 description 3
- XERLAFZWYABQAT-UHFFFAOYSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(NC1c(cc2)ccc2C#N)=O)=C1C(OCCO)=O Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(NC1c(cc2)ccc2C#N)=O)=C1C(OCCO)=O XERLAFZWYABQAT-UHFFFAOYSA-N 0.000 description 1
- SKLKKMQVGKXGGF-UHFFFAOYSA-N CC(N(c1cc(C(F)(F)F)ccc1)C(NC1c(cc2)ccc2C#N)=O)=C1C([n]1cncc1)=O Chemical compound CC(N(c1cc(C(F)(F)F)ccc1)C(NC1c(cc2)ccc2C#N)=O)=C1C([n]1cncc1)=O SKLKKMQVGKXGGF-UHFFFAOYSA-N 0.000 description 1
- DLEWDCPFCNLJEY-UHFFFAOYSA-N CCC(N1CCOCC1)=O Chemical compound CCC(N1CCOCC1)=O DLEWDCPFCNLJEY-UHFFFAOYSA-N 0.000 description 1
- USEAYZSFPSULAI-UHFFFAOYSA-N CCCN(CC)C(CI)=O Chemical compound CCCN(CC)C(CI)=O USEAYZSFPSULAI-UHFFFAOYSA-N 0.000 description 1
- HWFNNGYAXGHOJG-UHFFFAOYSA-N CCOC(C(C(c(cc1)ccc1C#N)N1)=C(C)N(c2cc(Cl)ccc2)C1=O)=O Chemical compound CCOC(C(C(c(cc1)ccc1C#N)N1)=C(C)N(c2cc(Cl)ccc2)C1=O)=O HWFNNGYAXGHOJG-UHFFFAOYSA-N 0.000 description 1
- TXBNFEKHANHAKM-UHFFFAOYSA-N CCOC(C(C(c(cc1)ccc1C#N)N1)=C(CBr)N(c2cc(C(F)(F)F)ccc2)C1=O)=O Chemical compound CCOC(C(C(c(cc1)ccc1C#N)N1)=C(CBr)N(c2cc(C(F)(F)F)ccc2)C1=O)=O TXBNFEKHANHAKM-UHFFFAOYSA-N 0.000 description 1
- SGUMGUMHXGRKPX-UHFFFAOYSA-N N#Cc1ncc(C2OCCO2)cc1 Chemical compound N#Cc1ncc(C2OCCO2)cc1 SGUMGUMHXGRKPX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0220962.5 | 2002-09-10 | ||
GB0220962A GB0220962D0 (en) | 2002-09-10 | 2002-09-10 | Heterocyclic derivatives |
GB0226609A GB0226609D0 (en) | 2002-09-10 | 2002-11-14 | Heterocyclic derivatives |
GB0226609.6 | 2002-11-14 | ||
GB0315870A GB2392910A (en) | 2002-09-10 | 2003-07-07 | 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors |
GB0315870.6 | 2003-07-07 | ||
PCT/EP2003/009525 WO2004024700A1 (en) | 2002-09-10 | 2003-08-28 | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2006507355A JP2006507355A (ja) | 2006-03-02 |
JP2006507355A5 JP2006507355A5 (ko) | 2009-09-10 |
JP4708034B2 true JP4708034B2 (ja) | 2011-06-22 |
Family
ID=39827677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004571738A Expired - Fee Related JP4708034B2 (ja) | 2002-09-10 | 2003-08-28 | 急性および慢性炎症、虚血およびリモデリング過程に対する治療剤としてのピリミジノン誘導体 |
Country Status (9)
Country | Link |
---|---|
JP (1) | JP4708034B2 (ko) |
AR (1) | AR042179A1 (ko) |
EC (1) | ECSP055669A (ko) |
ES (1) | ES2414865T3 (ko) |
GB (1) | GB2392910A (ko) |
HK (1) | HK1088304A1 (ko) |
PE (1) | PE20041078A1 (ko) |
TW (1) | TWI314555B (ko) |
UA (1) | UA82074C2 (ko) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA03008714A (es) | 2002-09-26 | 2004-09-10 | Oreal | Polimeros secuenciados y composiciones cosmeticas que comprenden tales polimeros. |
WO2004028493A2 (fr) * | 2002-09-26 | 2004-04-08 | L'oréal | Composition de revetement des fibres keratiniques ayant un extrait sec eleve comprenant un polymere sequence |
SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
FR2860143B1 (fr) | 2003-09-26 | 2008-06-27 | Oreal | Composition cosmetique comprenant un polymere sequence et une huile siliconee non volatile |
EP1723121B1 (en) * | 2004-02-26 | 2012-07-25 | Bayer Pharma Aktiengesellschaft | 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors |
EP1730121B1 (en) * | 2004-02-26 | 2013-08-07 | Bayer Intellectual Property GmbH | 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors |
TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
FR2904320B1 (fr) | 2006-07-27 | 2008-09-05 | Oreal | Polymeres sequences, et leur procede de preparation |
US20110003858A1 (en) * | 2006-09-04 | 2011-01-06 | Bergstroem Lena | Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors |
CL2008003301A1 (es) | 2007-11-06 | 2009-10-16 | Astrazeneca Ab | Compuestos derivados de 3,4-dihidropirazina-2-carboxamida, inhibidores de la elastasa de neutrofilos humanos; composiciones farmacéuticas; procesos de preparación de compuestos y composición farmacéutica; y uso en el tratamiento de síndrome de dificultad respiratoria de los adultos, fibrosis quística, cáncer, entre otras. |
ATE548355T1 (de) * | 2007-12-20 | 2012-03-15 | Bayer Pharma AG | 4- (4-cyano-2-thioaryl) -dihydropyrimidinone und ihre verwendung |
DE102008022521A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Schering Pharma Aktiengesellschaft | 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung |
ES2377809T3 (es) * | 2008-06-09 | 2012-04-02 | Bayer Pharma Aktiengesellschaft | Derivados condensados de la 4-(indazolil)-1,4-dihidropiridina como mediadores del c-Met |
TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
DE102009016553A1 (de) * | 2009-04-06 | 2010-10-07 | Bayer Schering Pharma Aktiengesellschaft | Sulfonamid- und Sulfoximin-substituierte Diaryldihydropyrimidinone und ihre Verwendung |
CN102639505A (zh) | 2009-10-02 | 2012-08-15 | 阿斯利康(瑞典)有限公司 | 用作嗜中性白细胞弹性蛋白酶抑制剂的吡啶-2-酮化合物 |
US20140221335A1 (en) | 2013-02-06 | 2014-08-07 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9115093B2 (en) | 2013-03-04 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
USRE47493E1 (en) | 2014-02-20 | 2019-07-09 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9475779B2 (en) | 2014-07-31 | 2016-10-25 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9458113B2 (en) | 2014-07-31 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9290457B2 (en) * | 2014-07-31 | 2016-03-22 | Boehringer Ingelheim International Gmbh | Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9440930B2 (en) * | 2014-07-31 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
-
2003
- 2003-07-07 GB GB0315870A patent/GB2392910A/en not_active Withdrawn
- 2003-08-27 AR ARP030103093A patent/AR042179A1/es unknown
- 2003-08-28 UA UAA200503292A patent/UA82074C2/uk unknown
- 2003-08-28 JP JP2004571738A patent/JP4708034B2/ja not_active Expired - Fee Related
- 2003-08-28 ES ES03773613T patent/ES2414865T3/es not_active Expired - Lifetime
- 2003-09-09 PE PE2003000910A patent/PE20041078A1/es not_active Application Discontinuation
- 2003-09-09 TW TW092124801A patent/TWI314555B/zh not_active IP Right Cessation
-
2005
- 2005-03-10 EC EC2005005669A patent/ECSP055669A/es unknown
-
2006
- 2006-07-31 HK HK06108489.5A patent/HK1088304A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GB2392910A (en) | 2004-03-17 |
ECSP055669A (es) | 2005-05-30 |
AR042179A1 (es) | 2005-06-15 |
TWI314555B (en) | 2009-09-11 |
GB0315870D0 (en) | 2003-08-13 |
UA82074C2 (uk) | 2008-03-11 |
HK1088304A1 (en) | 2006-11-03 |
JP2006507355A (ja) | 2006-03-02 |
PE20041078A1 (es) | 2005-02-25 |
TW200410963A (en) | 2004-07-01 |
ES2414865T3 (es) | 2013-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4708034B2 (ja) | 急性および慢性炎症、虚血およびリモデリング過程に対する治療剤としてのピリミジノン誘導体 | |
AU2003282006C1 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory ischaemic and remodelling processes | |
JP4601425B2 (ja) | ヒト好中球エラスターゼ阻害剤として使用するためのジヒドロピリジン誘導体 | |
JP4825195B2 (ja) | 1,4−ジアリール−ジヒドロピリミジン−2オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用 | |
JP4825194B2 (ja) | 1,4−ジアリール−ジヒドロピリミジン−2−オン化合物およびヒト好中球エラスターゼ阻害剤としてのそれらの使用 | |
JP5134248B2 (ja) | ジヒドロピリジノン誘導体 | |
JP4619122B2 (ja) | Hneインヒビターとしてのジヒドロピリジノン誘導体 | |
EP1539710B1 (en) | Heterocyclic derivatives | |
JP4708025B2 (ja) | ヘテロ環誘導体 | |
RU2376295C2 (ru) | Производные пиримидинона и фармацевтическая композиция на их основе, обладающая свойствами ингибитора нейтрофильной эластазы человека | |
CN100575346C (zh) | 嘧啶酮衍生物作为治疗药物治疗急性和慢性炎性、缺血性和重建性病变 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060823 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090624 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091026 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20091026 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20091026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100119 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100402 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100409 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100720 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100720 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100831 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101222 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110125 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110316 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4708034 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140325 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140325 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |